Role of Toll-like receptor 3 in the immunoregulatory function of embryonic bone marrow mesenchymal stem cells on Th17 cells

doi:10.3969/j.issn.2095-4344.2014.45.001

Abstract

Abstract:

BACKGROUND: Previous studies have found that embryonic bone marrow mesenchymal stem cells can promote human Th17 cell proliferation, but the inherent regulatory mechanisms still need to be elucidated.

OBJECTIVE: To investigate the role of Toll-like receptor 3 in the immunoregulation of Th17 cells by mesenchymal stem cells.

METHODS: Human CD4⁺ T cells from healthy donors were isolated by immunomagnetic bead method, and then cultured alone or co-cultured with embryonic bone marrow mesenchymal stem cells for 4 days. The mRNA expression level of interleukin-17, Toll-like receptor 3 and MyD88 was detected by real-time PCR.

RESULTS AND CONCLUSION: Compared with CD4⁺ T cell cultured alone group, the mRNA level of interleukin-17 was significantly higher in the co-culture group (3.59±0.11 vs. 1.14± 0.08, P < 0.01). Consistent with the expression of interleukin-17 mRNA, increased level of Toll-like receptor 3 mRNA was detected in the co-culture group compared with the CD4⁺ T cell cultured alone group (3.10±1.60 vs. 0.94± 0.01, P < 0.05). Furthermore, MyD88 in the co-culture group was significantly higher than that in CD4⁺ T cell cultured alone group (2.29±0.05 vs. 1.85±0.31, P < 0.01). Toll-like receptor 3 may be involved in the immunoregulation of Th17 cells by embryonic bone marrow mesenchymal stem cells, which provides experimental evidence for potential cell therapeutic strategy.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: mesenchymal stem cells, toll-like receptor 3, Th17 cells, immunomodulation

CLC Number:

R394.2

Guo Zhen-xing, Chen Zhen-ping. Role of Toll-like receptor 3 in the immunoregulatory function of embryonic bone marrow mesenchymal stem cells on Th17 cells[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(45): 7217-7221.

Figures/Tables 4

References

[1]Aggarwal S, Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood. 2005; 105(4):1815-1822.
[2]Meisel R, Zibert A, Laryea M,et al.Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.Blood. 2004;103(12):4619-4621.
[3]Glennie S, Soeiro I, Dyson PJ,et al.Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.Blood. 2005;105(7):2821-2827.
[4]Krampera M, Cosmi L, Angeli R, et al.Role for interferon- gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells.Stem Cells. 2006; 24(2): 386-398.
[5]Le Blanc K, Rasmusson I, Sundberg B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.Lancet. 2004;363 (9419):1439-1441.
[6]Bartholomew A, Sturgeon C, Siatskas M,et al.Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol. 2002;30(1):42-48.
[7]Zhang J, Li Y, Chen J,et al.Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice.Exp Neurol. 2005;195(1):16-26.
[8]Lazarus HM, Koc ON, Devine SM,et al.Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.Biol Blood Marrow Transplant. 2005;11(5):389-398.
[9]Guo Z, Zheng C, Chen Z,et al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells.Eur J Immunol. 2009;39(10):2840-2849.
[10]Schirmer C, Klein C, von Bergen M,et al.Human fibroblasts support the expansion of IL-17-producing T cells via up-regulation of IL-23 production by dendritic cells.Blood. 2010;116(10):1715-1725.
[11]Eljaafari A, Tartelin ML, Aissaoui H,et al.Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis.Arthritis Rheum. 2012;64(7):2147-2157.
[12]Fischer M, Ehlers M.Toll-like receptors in autoimmunity.Ann N Y Acad Sci. 2008;1143:21-34.
[13]Dominici M, Le Blanc K, Mueller I,et al.Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
[14]Krishnan J, Selvarajoo K, Tsuchiya M,et al.Toll-like receptor signal transduction.Exp Mol Med. 2007;39(4):421-438.
[15]Wang Y, Xie J, Wang N,et al.Lactobacillus casei Zhang modulate cytokine and Toll-like receptor expression and beneficially regulate PolyI:C-induced immune responses in RAW264.7 macrophages.Microbiol Immunol. 2013;57(1): 54-62.
[16]Kamran N, Takai Y, Miyoshi J,et al.Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells.PLoS One. 2013;8(1):e54406.
[17]Wu J, Meng Z, Jiang M,et al.Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.Immunology. 2010;129(3):363-374.
[18]St Paul M, Barjesteh N, Paolucci S,et al.Toll-like receptor ligands induce the expression of interferon-gamma and interleukin-17 in chicken CD4+ T cells.BMC Res Notes. 2012; 5:616.
[19]Bach NS, Låg M, Øvrevik J.Toll like receptor-3 priming alters diesel exhaust particle-induced cytokine responses in human bronchial epithelial cells.Toxicol Lett. 2014;228(1):42-47.
[20]Saluja R, Delin I, Nilsson GP,et al.FcεR1-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment.PLoS One. 2012;7(8):e43547.
[21]Mitchell D, Olive C.Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases.Mol Immunol. 2010;47 (11-12):2065-2073.
[22]McKernan DP, Dennison U, Gaszner G,et al.Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype.Transl Psychiatry. 2011;1:e36.
[23]Chin AI, Miyahira AK, Covarrubias A,et al.Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.Cancer Res. 2010;70(7):2595-2603.
[24]Meng L, Zhu W, Jiang C,et al.Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats.Arthritis Res Ther. 2010; 12(3): R103.
[25]Liu Z, Guan Y, Sun X,et al.HSV-1 activates NF-kappaB in mouse astrocytes and increases TNF-alpha and IL-6 expression via Toll-like receptor 3.Neurol Res. 2013;35(7): 755-762.
[26]刘婧,刘水平,古力娜尔•库尔班,等. Toll样受体3信号通路在人类病毒性心肌炎心肌细胞凋亡及炎症反应中的作用[J].中国病理生理杂志,2013,29(3):404-407.
[27]Liotta F, Angeli R, Cosmi L,et al.Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling.Stem Cells. 2008;26(1):279-289.
[28]Tomchuck SL, Zwezdaryk KJ, Coffelt SB,et al.Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses.Stem Cells. 2008;26(1):99-107.
[29]Kattah MG, Wong MT, Yocum MD,et al.Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells.Arthritis Rheum. 2008; 58(6):1619-1629.
[30]Lombardi V, Van Overtvelt L, Horiot S,et al.Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.J Immunol. 2009;182(6):3372-3379.
[31]Tanaka J, Watanabe N, Kido M,et al.Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions.Clin Exp Allergy. 200;39(1):89-100.
[32]Fukata M, Breglio K, Chen A,et al.The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.J Immunol. 2008;180(3):1886-1894.